Cercador de l’activitat científica d’IrsiCaixa

An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults | AbiVax 005

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals

Centres participants: Hospital Germans Trias i Pujol, IrsiCaixa, AELIX Therapeutics

A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI with Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted with MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

Immune response to SARS-CoV-2 vaccine in institutionalized elders: the challenge for a long-term immunity

Centres participants: ICASS long-term care facilities, IrsiCaixa AIDS Research Institute

Pool testing screening study for faster and more efficient screening of the prevalence of SARS-CoV-2 infection in the northern metropolitan area

Centres participants: Germans Trias i Pujol University Hospital, Fight Infections Foundation, IrsiCaixa AIDS Research Institute

Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (ART) in HIV-1 reservoir and in peripheral compartments in HIV-infected patients

Centres participants: Germans Trias i Pujol University Hospital, Fight Infections Foundation, IrsiCaixa AIDS Research Institute, University of North Carolina, Oregon Health & Sciences University

Assaig clínic per avaluar l’efecte del durvalumab (MEDI4736) en pacients VIH-positius amb tumors sòlids avançats | Durvast

Estudi clínic observacional, per avaluar l’efecte dels trasplantaments al·logènics en pacients VIH-positius amb malalties hematològiques malignes | IciStem

Estudi en fase IIa d'intervenció, multicèntric, doble cec, controlat amb placebo per avaluar la seguretat i la immunogenicitat de la nova vacuna terapèutica iHIVARNA-01 en pacients infectats pel VIH | iHIVARNA-02

Centres participants: Erasmus MC, Rotterdam, Països Baixos; Hospital Clínic de Barcelona i Hospital Germans Trias i Pujol -Fundació Lluita contra la Sida, Institut de Recerca de la Sida IrsiCaixa- de Badalona, Espanya; Instituut voor Tropische Geneeskunde d’Anberes, Bèlgica.

Prospective Comparative Observational Cohort of individuals with documented SARS-CoV-2 infection (King cohort extension)

Centres participants: Germans Trias i Pujol University Hospital, Fight Infections Foundation, IrsiCaixa AIDS Research Institute